Bluejay Diagnostics (BJDX) stock rocketed higher on Thursday after the medical diagnostics company announced an expanded partnership with Japan-based medical device and precision engineering company SanyoSeiko. This expansion increased SanyoSeiko’s role in helping with the commercialization of Bluejay Diagnostics’ Symphony platform. Symphony is a patient testing system dedicated to providing rapid and reliable results for key biomarkers.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Under the terms of this agreement, SanyoSeiko will provide end-to-end support for the Symphony platform. That includes supporting the manufacturing redevelopment process for analyzers and cartridges, managing raw material sourcing and vendor compliance, and serving as the contract manufacturer for analyzers, cartridges, and related components.
Neil Dey, CEO of Bluejay, said, “This expanded partnership marks a key milestone in Bluejay’s commercialization strategy for the Symphony platform. By formalizing SanyoSeiko’s role as manufacturing partner, we strengthen our supply chain resilience, secures high-quality production capacity, and advances readiness for broader clinical validation and market introduction.”
Bluejay Diagnostics Stock Movement Today
Bluejay Diagnostics stock was up 114.44% in pre-market trading on Thursday, following a 12.62% drop yesterday. The shares have fallen 61.6% year-to-date and 68.28% over the past 12 months. With today’s news came heavy trading, as some 40 million shares changed hands, compared to a three-month daily average of about 154,000 units.
Is Bluejay Diagnostics Stock a Buy, Sell, or Hold?
Turning to Wall Street, analyst coverage of Bluejay Diagnostics is lacking. Fortunately, TipRanks’ AI analyst Spark has it covered. Spark rates BJDX stock an Underperform (29) with no price target. It cites “poor financial performance, with no revenue and continuous losses” as reasons for this stance.
